Contributors ix
Preface xxi
About the Society for Immunotherapy of Cancer xxv
Acknowledgments xxvii
Abbreviation List xxix
1. History of Cancer Immunotherapy 1
Michael T. Lotze and Michael B. Atkins
SECTION ONE: BASIC PRINCIPLES OF TUMOR
IMMUNOLOGY
Francesco M. Marincola
2. Introduction to Basic Sciences: The Caduceus
of Cancer-Immune Responsiveness and Cancer
Biology 18
Francesco M. Marincola and Michael T. Lotze
3. Genomic Determinants of Cancer Immune
Response and Resistance 25
Alessandra Cesano
4. Human Tumor Antigens Recognized by T
Lymphocytes 31
Nicolas van Baren and Pierre G. Coulie
5. Structural and Functional Defects in HLA Class
I Antigen Processing Machinery in Cancer
Cells: Molecular Mechanisms and Clinical
Relevance 41
Lei Cai, Theodoros Michelakos, Teppei Yamada,
Luke Maggs, Ananthan Sadagopan, Joseph H. Schwab,
Cristina R. Ferrone, and Soldano Ferrone
6. Systems Biology of T Cells 59
David Furman and Yingxiang Huang
7. Activation of CD4+ T Lymphocytes 72
Lina Petersone and Lucy S. K. Walker
8. Regulation of Cell-Mediated Immunity: The Biology
of Checkpoints and Regulatory T Cells 80
Lucy S. K. Walker and Lina Petersone
9. B Cells in Solid Tumors: Their Role in Tumor
Pathogenesis and Antitumor Immunity 90
Muhammad Husnain, Yu Zhang, and
Joseph D. Rosenblatt
Contents
vi Contents
SECTION TWO: CANCER IMMUNOTHERAPY
TARGETS AND CLASSES
Howard L. Kaufman
21. Introduction to Principles of Cancer
Immunotherapy 242
Jon M. Wigginton
22. Manipulating Innate Immune Pathways for Cancer
Immunotherapy 255
Olivier Demaria, Thomas F. Gajewski, and
Eric Vivier
23. Cancer Vaccines: Considerations of Antigen,
Formulation, and Delivery 274
Alena Donda, Mathias Wenes, Margaux Saillard, and
Pedro Romero
24. T Cell Modulatory Cytokines 285
Emanuela Romano and Kim Margolin
25. Non-Engineered Adoptive T Cell Therapy 299
Farah Hasan and Cassian Yee
26. CAR T Cell Therapy 313
Shivani Srivastava, Alexander I. Salter, and
Stanley R. Riddell
27. Immunotherapy Based on Blocking T Cell
Inhibitory Pathways 332
Randy F. Sweis and Jason J. Luke
28. Agonistic Antibodies to Co-Stimulatory
Molecules 348
Rebekka Duhen, Alexandra K. Frye, and
Andrew D. Weinberg
29. Immune Effects of Conventional Cancer
Therapeutics 368
Sandra Demaria, Giulia Petroni, and Lorenzo Galluzzi
30. Oncolytic Viruses 386
Ragunath Singaravelu, Larissa Pikor, John Bell, and
Howard L. Kaufman
31. Metabolism of Tumor Immunity 410
Robert D. Leone and Jonathan D. Powell
32. Principles of Combination
Immunotherapies 421
Inderjit Mehmi, Raphael Brandao, Omid Hamid, and
Patrick A. Ott
SECTION THREE: IMMUNE FUNCTION IN
CANCER PATIENTS
Lisa H. Butterfield
33. Introduction to Immune Function in
Cancer Patients 442
Lisa H. Butterfield
34. Tumor-Infiltrating Myeloid Cells in Cancer
Progression and Therapy Response 444
Sushil Kumar, Amanda Poissonnier, Courtney B. Betts,
Dhaarini Murugan, Eivind Valen Egeland,
Femke Ehlers, Jacklyn Woods, Nicky Beelen,
and Lisa M. Coussens
35. Intratumoral Gene Signatures and Host
Genetic Variations Associated With Immune
Responsiveness 462
Davide Bedognetti, Eiman I. Ahmed, Jessica Roelands,
Zohreh Tatari-Calderone, Francesco M. Marincola, and
Ena Wang
36. Impact of Somatic Mutations on the Local and
Systemic Antitumor Immune Response 486
Paul F. Robbins
37. Tumor Antigen Profiling 498
Robert Saddawi-Konefka, Bryan S. Yung, and
Jack D. Bui
38. Assessment of Antitumor Immunity in Blood and
Lymph Nodes 511
Priyanka B. Subrahmanyam, Lei Wang,
Lisa H. Butterfield, Peter P. Lee, and Holden T. Maecker
39. Regulatory T Cell Biology and Its Applications in
Cancer Immunotherapy 520
Michael R. Pitter and Weiping Zou
40. Systemic Measures of Immune Function in
Cancer Patients: Other Suppressive Cellular
Mechanisms 536
Thomas A. Mace, Raju R. Raval, and
William E. Carson III
41. Circulating Mediators of Tumor-Induced Immune
Suppression 543
Theresa L. Whiteside
42. Harnessing B Cells and Tertiary Lymphoid
Structures for Antitumor Immunity 548
Ayana T. Ruffin and Tullia C. Bruno
43. Blood Transcriptomic Approaches to Cancer
Immunotherapy 562
Darawan Rinchai, Davide Bedognetti, and
Damien Chaussabel
44. Advances in Techniques for Immunotherapy
Biomarker Analysis 574
Theresa M. LaVallee, Pier Federico Gherardini, and
Cheryl Selinsky
45. Predictive Biomarkers (Programmed Death Ligand
1 Expression, Microsatellite Instability, and Tumor
Mutational Burden) for Response to Immune
Checkpoint Inhibitors 591
Kenneth Emancipator, Jianda Yuan, Razvan Cristescu,
Deepti Aurora-Garg, and Priti S. Hegde
Contents vii
46. Tumor Microenvironment Metabolism as a
Primordial Checkpoint in Antitumor T Cell
Immunity 604
Greg M. Delgoffe
47. Age-Related Immune Function Changes as They
Relate to Cancer Immunotherapy 612
Graham Pawelec and Emilie Picard
48. Clinical Measures: Tumor Response Assessments,
Pseudoprogression, and Immunometabolism 617
Louis F. Chai and Steven C. Katz
SECTION FOUR: DISEASE-SPECIFIC
TREATMENTS AND OUTCOMES
Paolo A. Ascierto
49. Introduction: General Approach to Cancer
Immunotherapy—Lessons Learned From
the Past Years 636
Paolo A. Ascierto
50. Immunotherapy in Melanoma 647
Antonio Maria Grimaldi, Igor Puzanov, and
Paolo A. Ascierto
51. Other Cutaneous Tumors: Basal Cell Carcinoma,
Cutaneous Squamous Cell Carcinoma, Merkel Cell
Carcinoma, and Cutaneous Sarcomas 671
Jürgen C. Becker, Shailender Bhatia,
Alexander Guminski, and Selma Ugurel
52. Immunotherapy in Genitourinary
Malignancies 682
Moshe C. Ornstein and Brian I. Rini
53. Immunotherapy in Gastrointestinal
Malignancies 698
Dave R. Gupta, Usha Malhotra, and Mihir M. Shah
54. Immunotherapy of Hepatocellular
Carcinoma 707
Piera Federico, Margaret Ottaviano, and Bruno Daniele
55. Immunotherapy for Gynecologic
Malignancies 717
Kunle Odunsi, Thinle Chodon, and Cornelia L. Trimble
56. Breast Cancer Immunotherapy 730
Leisha A. Emens and Rita Nanda
57. Immunotherapy for Lung Cancer and Malignant
Pleural Mesothelioma 744
Paola Ghanem and Julie R. Brahmer
58. Head and Neck Cancer 759
Nicole C. Schmitt and Robert L. Ferris
59. Immunotherapy of Hematologic Malignancies:
Lymphomas, Leukemias, and Myeloma 773
Adrian Bot, John M. Timmerman, and
Patricia A. Young
60. Brain Tumors 791
Hideho Okada and Noriyuki Kasahara
61. Sarcomas 812
Seth M. Pollack
62. Pediatric Cancers: Neuroblastoma 821
Maya Suzuki and Nai-Kong V. Cheung
63. Immunotherapy in Combination With
Radiation Therapy 839
Jean Philippe Nesseler, William H. McBride, and
Dörthe Schaue
SECTION FIVE: REGULATORY ASPECTS OF THE
BIOLOGICAL THERAPY OF CANCER
Raj K. Puri
64. Regulatory Considerations for Therapeutic
Cancer Vaccines 854
Syed R. Husain, Karin M. Knudson, Laronna Colbert,
Ramjay S. Vatsan, Thomas Finn, Jaikumar Duraiswamy,
Ke Liu, and Raj Puri
65. A Regulatory Perspective on Cell Therapy for
Cancer: Chemistry, Manufacturing and Control,
Preclinical, and Clinical Considerations 869
Ke Liu, Jaikumar Duraiswamy, Thomas Finn,
Brian Niland, Allen Wensky, and Raj Puri
66. Gene Therapy-Based Immunotherapy Products for
Human Clinical Trials: Chemistry, Manufacturing
and Control, Preclinical, and Clinical
Considerations: An FDA Perspective 883
Ramjay S. Vatsan, Y Nguyen, Allen Wensky,
Chaohong Fan, Ke Liu, and Raj Puri
67. Combination Immunotherapies: Regulatory
Considerations 906
Ke Liu, Marc Theoret, Allen Wensky, Thomas Finn,
Ramjay S. Vatsan, and Raj Puri
68. Regulatory Considerations for In Vitro Companion
Diagnostic Devices 911
Shyam Kalavar, Pamela Gallagher, Reena Philip, and
Wendy Rubinstein
Index 919
Cancer Immunotherapy Principles and Practice 2nd Edition PDF Ebook
